Good Life Advisors LLC Buys New Shares in Danaher Corporation $DHR

Good Life Advisors LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,650 shares of the conglomerate’s stock, valued at approximately $326,000.

A number of other large investors also recently modified their holdings of the company. WASHINGTON TRUST Co raised its stake in shares of Danaher by 15.0% during the second quarter. WASHINGTON TRUST Co now owns 4,771 shares of the conglomerate’s stock worth $942,000 after acquiring an additional 623 shares in the last quarter. ABN Amro Investment Solutions bought a new stake in Danaher in the second quarter worth $92,327,000. Candriam S.C.A. lifted its stake in Danaher by 12.3% in the second quarter. Candriam S.C.A. now owns 451,933 shares of the conglomerate’s stock worth $89,279,000 after purchasing an additional 49,409 shares during the last quarter. Impax Asset Management Group plc boosted its position in Danaher by 37.3% during the second quarter. Impax Asset Management Group plc now owns 521,998 shares of the conglomerate’s stock valued at $102,288,000 after buying an additional 141,824 shares during the period. Finally, Calamos Advisors LLC grew its stake in shares of Danaher by 27.6% during the second quarter. Calamos Advisors LLC now owns 259,681 shares of the conglomerate’s stock valued at $51,297,000 after buying an additional 56,208 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

NYSE:DHR opened at $221.25 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The firm’s fifty day simple moving average is $205.63 and its 200 day simple moving average is $201.09. The stock has a market cap of $156.28 billion, a P/E ratio of 45.62, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $258.23.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.71 EPS. As a group, research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were issued a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on DHR shares. Rothschild Redb cut Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Bank of America cut their target price on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 10th. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a research report on Thursday, October 23rd. Finally, Guggenheim reissued a “buy” rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 29,728 shares of company stock valued at $6,448,990. Corporate insiders own 11.20% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.